^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PALB2 (Partner and localizer of BRCA2)

    i
    Apply
    Assessing Clinical Features and Outcome of Breast Cancer in PALB2 Mutation Carriers: the Palbreast Study (PALBREAST) (NCT06403904)
    Phase N/A
    Azienda Ospedaliero-Universitaria di Modena
    Recruiting
    Last update posted :
    05/08/2024
    Initiation :
    10/02/2023
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    PALB2 • BRCA
    A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (NEO) (NCT02489006)
    Phase 2
    University Health Network, Toronto
    Active, not recruiting
    Last update posted :
    01/17/2024
    Initiation :
    07/19/2016
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    BRCA1 • BRCA2 • PALB2 • RAD51B • BRIP1 • RAD51C • PARP1 • RAD51D • BARD1 • PPM1D • FANCM
    |
    PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation
    |
    Lynparza (olaparib)
    A Study of Participants With Advanced Prostate Cancer in Canada (GURC) (NCT03501173)
    Phase N/A
    Janssen Inc.
    Completed
    Last update posted :
    07/25/2023
    Initiation :
    04/12/2018
    Primary completion :
    07/14/2023
    Completion :
    07/14/2023
    BRCA1 • BRCA2 • AR • HRD • PALB2
    |
    ATM mutation • PALB2 mutation
    Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk (NCT02478892)
    Phase N/A
    Abramson Cancer Center at Penn Medicine
    Recruiting
    Last update posted :
    07/19/2023
    Initiation :
    05/01/2015
    Primary completion :
    05/01/2025
    Completion :
    05/01/2027
    BRCA1 • BRCA2 • ATM • PALB2
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation
    Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. (RADIOLA) (NCT05340413)
    Phase 2
    SOLTI Breast Cancer Research Group
    Recruiting
    Last update posted :
    04/18/2023
    Initiation :
    03/25/2022
    Primary completion :
    04/01/2024
    Completion :
    06/01/2024
    HER-2 • PGR • BRCA1 • BRCA2 • HRD • PALB2 • RAD51 • RAD51C • RAD51D
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 amplification • HER-2 negative • PALB2 mutation • ER positive + PGR positive • PGR positive • RAD51C mutation • RAD51D mutation • PGR negative • RAD51 mutation
    |
    Lynparza (olaparib)
    Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study) (NCT03377556)
    Phase 2
    Southwest Oncology Group
    Completed
    Last update posted :
    06/23/2021
    Initiation :
    03/03/2017
    Primary completion :
    01/10/2021
    Completion :
    04/16/2021
    BRCA1 • BRCA2 • HRD • PALB2 • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • CHEK1 • BARD1 • NBN • RAD54L • FANCF • FANCM • FANCD2 • RPA1 • FANCC
    |
    BARD1 mutation • RPA1 mutation
    |
    Talzenna (talazoparib)
    Molecular Profiling of Advanced Biliary Tract Cancers (NCT03419247)
    Phase N/A
    University Health Network, Toronto
    Withdrawn
    Last update posted :
    04/01/2021
    Initiation :
    01/01/2020
    Primary completion :
    01/02/2022
    Completion :
    01/02/2023
    ATM • PALB2 • BRCA
    |
    ATM mutation • PALB2 mutation • BRCA mutation
    Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan (CUARTET) (NCT04601441)
    Phase 4
    Kindai University
    Recruiting
    Last update posted :
    12/08/2020
    Initiation :
    11/06/2020
    Primary completion :
    03/31/2025
    Completion :
    03/31/2025
    KRAS • BRAF • TP53 • PIK3CA • BRCA1 • BRCA2 • PTEN • IDH1 • IDH2 • CDKN2A • RB1 • ARID1A • AKT1 • RUNX1 • ASXL1 • CCND1 • PALB2 • MLH1 • KMT2D • MSH6 • CDK4 • MSH2 • RNF43 • CDK12 • CTNNB1 • ERCC1 • ERCC2 • FBXW7 • KMT2C • FANCA • RAD51B • KDM6A • MDM4 • PIK3R1 • RAD51C • CDK6 • PIK3CB • SPOP • FOXA1 • GNAS • ZFHX3 • AKT2 • CHD1 • CUL1 • ERCC5 • FANCF • FOXP1 • ERCC4 • CDKN1B • ERCC3 • FANCD2 • FANCE • FANCG • HSD3B1 • ZBTB16 • FANCC • NCOA2 • NKX3-1
    |
    apalutamide
    Prospective Multicentre Cohort Study PROREPAIR-B (mCRPC) (NCT03075735)
    Phase N/A
    Centro Nacional de Investigaciones Oncologicas ...
    Completed
    Last update posted :
    02/04/2019
    Initiation :
    01/15/2013
    Primary completion :
    05/01/2018
    Completion :
    12/15/2018
    BRCA1 • BRCA2 • PALB2
    |
    PALB2 mutation